MYGN — Myriad Genetics Share Price

As of Today at 19:15 UTC, shares in Myriad Genetics are trading at $18.50. This share price information is delayed by 15 minutes.

Shares in Myriad Genetics last closed at $18.50 and the price had moved by -15.45% over the past 365 days. In terms of relative price strength the Myriad Genetics share price has underperformed the S&P500 Index by -29.64% over the past year.

The overall consensus recommendation for Myriad Genetics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

Myriad Genetics does not currently pay a dividend.

Myriad Genetics does not currently pay a dividend.

Myriad Genetics does not currently pay a dividend.

To buy shares in Myriad Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

As of the previous close price of $18.50, shares in Myriad Genetics had a market capitalisation of $1.67bn.

Here are the trading details for Myriad Genetics: 

• Country of listing: United States
• Exchange: NSQ
• Ticker Symbol: MYGN

Based on an overall assessment of its quality, value and momentum Myriad Genetics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

The analyst consensus target price for shares in Myriad Genetics is $23.91.  That is 29.24% above the last closing price of $18.50.

Analysts covering Myriad Genetics currently have a consensus Earnings Per Share (EPS) forecast of $0.02 for the next financial year.

An important predictor of whether a stock price will go up is its track record of momentum.  Price trends tend to persist, so it's worth looking at them when it comes to a share like Myriad Genetics. Over the past six months, its share price has outperformed the S&P500 Index by +4.22%.

As of the last closing price of $18.50, shares in Myriad Genetics were trading -3.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

The Myriad Genetics PE ratio based on its reported earnings over the past 12 months is 220.03. The shares last closed at $18.50. 

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Myriad Genetics' management team is headed by: 

• S. Louise Phanstiel - CHM
• Paul Diaz - PRE
• R. Bryan Riggsbee - CFO
• Melissa Gonzales - CEX
• Mark Verratti - CEX
• Faith Zaslavsky - CEX
• Nicole Lambert - COO
• Benjamin Jackson - EVP
• Jayne Hart - EVP
• Paul Parkinson - EVP
• Jeff Borcherding - SVP
• Maggie Ancona - SVP
• Edward Gala - SVP
• David Hammer - SVP
• Chris Williamson - SVP
• Kevin Haas - CTO
• Justin Hunter - VPR
• Karen Renner - VPR
• Jackie Zou - VBD
• Eric Santa - OTH
• Thomas Slavin - OTH
• Gwendolyn Turner - OTH
• Pamela Wong - OTH
• Heiner Dreismann - IND
• Rashmi Kumar - IND
• Dennis Langer - IND
• Lee Newcomer - IND
• Colleen Reitan - IND
• Daniel Skovronsky - IND
• Daniel Spiegelman - IND